Anhui Anke Biotechnology (300009.SZ): Innovative drug HuA21 injection to release clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting.

Anhui Anke Biotechnology (300009.SZ) announced that at the European Society for Medical Oncology (ESMO) Annual Meeting held in Berlin, Germany from October 17th to 21st, 2025, the company presented the latest research results of its independently developed bio-innovative drug HuA21, a recombinant anti-HER2 humanized HuA21 monoclonal antibody injection, in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma in phase Ib/II dose escalation and expansion studies. The clinical research data presented at the ESMO Annual Meeting on the combination of HuA21 and trastuzumab with chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma further confirms its good anti-tumor activity and tolerable safety, providing support for phase III clinical trials and accelerating drug development. Furthermore, the positive clinical data will provide strong support for the product's market prospects, enhancing the future market competitiveness of the company's products.